We found that combination of doxorubicin chemotherapy and Apo2L/TRAIL is more effective in tumor growth inhibition than either agent alone, indicating that this may represent a novel treatment strategy against prostate cancer. The gene discussed is TNFSF10; the disease is neoplasm.